CPG
CRSP icon

Cornerstone Planning Group’s CRISPR Therapeutics CRSP Stock Holding History

Cornerstone Planning Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.2K Hold
300
– – ﹤0.01% 786
2026
Q1 		$15.7K Buy
300
+200
+200% +$10.5K ﹤0.01% 750
2025
Q4 		$5.37K Buy
+100
New +$5.99K ﹤0.01% 966

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Cornerstone Planning Group's CRSP Position: Q2 2026 in Review

Cornerstone Planning Group held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 300 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #786.

Cornerstone Planning Group first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $15.7K in Q1 2026. 284 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Cornerstone Planning Group held 300 shares of CRISPR Therapeutics worth $14.2K as of Q2 2026.
  • Cornerstone Planning Group left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #786 holding.
  • Cornerstone Planning Group first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Cornerstone Planning Group's CRISPR Therapeutics position peaked at $15.7K in Q1 2026.
  • 284 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.